Linaclotide Capsules 72 Mcg

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of linaclotide capsules 72 mcg in China. Welcome to wholesale bulk high quality linaclotide capsules 72 mcg for sale here from our factory. Good service and reasonable price are available.

Linaclotide capsules 72 mcg primarily act on the guanylate cyclase-C (GC-C) receptor in the intestines.Linaclotide is a chemical substance with the molecular formula C59H79N15O21S6 and CAS registry number 851199-59-2. They promote intestinal fluid secretion, accelerate intestinal motility, and can also reduce visceral hypersensitivity in the gut. As a guanylate cyclase-C (GC-C) agonist, linaclotide targets intestinal receptors. Linaclotide are available in different dosages, with common specifications including 72 mcg, 290 mcg, and 145 mcg.The capsules are clinically available in three common dosage strengths: 72, 145, and 290 mcg, with the specific dose selected based on the severity of the patient's condition, symptom presentation, and individual tolerance to achieve precision medication.

Linaclotide COA

Certificate of Analysis
Compound name	Linaclotide
Grade	Pharmaceutical grade
CAS No.	851199-59-2
Quantity	35g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090036
MFG	Jan 9th 2025
EXP	Jan 8th 2028
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

Therapeutic Areas

 

Linaclotide capsules 72 mcg is a targeted guanylate cyclase-C (GC-C) agonist that exerts its therapeutic effects exclusively within the intestinal lumen. By selectively binding to and activating GC-C receptors on the inner epithelial lining, it triggers a cascade that elevates intracellular cyclic GMP (cGMP) levels. This elevation directly stimulates the secretion of chloride and water into the gut, thereby hydrating and softening stool, while also modulating visceral sensory nerves to reduce abdominal pain. Consequently, it not only accelerates intestinal transit but also effectively normalizes bowel function and alleviates discomfort. The core therapeutic areas and related details are expanded below:

Chronic Idiopathic Constipation

It significantly increases the frequency of spontaneous bowel movements per week, softens stool consistency, reduces straining during defecation, and alleviates the sensation of incomplete evacuation. It also helps relieve abdominal bloating and discomfort caused by long-term constipation.
For cases where traditional laxatives are ineffective, it is one of the first-line treatment options, significantly improving quality of life.

Irritable Bowel Syndrome with Constipation

• It is indicated for : cases where constipation is the main symptom, accompanied by recurrent abdominal pain, bloating, or discomfort, and where symptoms are related to bowel movements (e.g., relief of abdominal pain after defecation).
• Symptom improvement : Dual action-it not only addresses core constipation symptoms (bowel movement frequency, stool consistency) but also alleviates IBS-specific discomforts such as abdominal pain and bloating.
• Additional value : Unlike traditional laxatives, linaclotide simultaneously targets the combined symptoms of IBS-C, including both "constipation + abdominal pain/bloating." 

Linaclotide capsules 72 mcg is a guanylate cyclase-C (GC-C) agonist that exerts its therapeutic effects by activating GC-C receptors in the intestines, thereby regulating intestinal secretion and motility. But how does it reduce visceral hypersensitivity in the intestines?

Linaclotide alleviates abdominal pain associated with visceral hypersensitivity primarily through its role as a guanylate cyclase-C (GC-C) agonist. Its action is localized, confined to the intestinal lumen, where it binds to GC-C receptors on epithelial cells. This binding stimulates a key signaling molecule, cyclic guanosine monophosphate (cGMP), which then acts on two fronts: first, it directly suppresses the activity of local pain-sensing nerves (nociceptors); second, it is partially extruded into the extracellular space to act on adjacent afferent nerve endings, reducing their excitability. Through this dual modulation of intestinal sensory signaling pathways, it achieves its analgesic effect. The specific pathways involved are detailed as follows:

Activation of GC-C Receptors and Initiation of Signaling Pathways

 

By binding to GC-C receptors on intestinal epithelial cells, linaclotide stimulates the intracellular production of cyclic guanosine monophosphate (cGMP). This molecule not only serves as a key factor in regulating intestinal secretion and motility but also plays a role in modulating intestinal sensory transmission.

Inhibition of Sensory Nerve Overexcitement

 

Intracellular cGMP acts on sensory nerve endings in the intestinal submucosa, raising the threshold for neural responses to intestinal distension. This reduces the transmission of abnormal pain signals to the central nervous system, thereby alleviating abdominal pain and bloating.

Improvement of the Intestinal Microenvironment and Indirect Regulation of Sensitivity

 

Linaclotide capsule 72 Mcg promotes intestinal motility and bowel movements, reducing the retention of metabolic waste and harmful bacteria. It also helps repair the intestinal mucosal barrier, balance the gut microbiota, and lower the levels of inflammatory factors, further alleviating intestinal sensitivity.

Linaclotide acts locally within the intestines and does not enter the systemic circulation, resulting in a higher safety profile.

The common specifications of this capsules are 72 mcg, 290 mcg, and 145 mcg. Their core mechanism of action involves activating the GC-C receptors on the surface of intestinal epithelial cells, which produces two core effects

Stimulating intestinal epithelial cells to secrete chloride and bicarbonate ions, thereby promoting the influx of water into the intestinal lumen, softening stool, and increasing stool volume.

Modulating the sensitivity of visceral sensory nerves in the intestines, reducing excessive contractions of intestinal smooth muscle, and alleviating discomforts such as abdominal pain and bloating.

The clinical application of Linaclotide capsules 72 mcg is centered on its core role in regulating intestinal function, with a focus on clinical treatment and related medical scenarios. It can be specifically categorized as follows: 

Exploration of Clinical Extended Applications

Clinical studies have explored linaclotide as adjunctive treatment for other functional bowel disorders, but these applications remain non-mainstream and require more clinical data support.

Secondary research-industry reports, regulatory updates, competitor analysis-provides broader context. Continuous research keeps strategies aligned with market changes.

Formulation and Medication Scenarios

Formulated as oral capsules with once-daily dosing, this capsule suits long-term home/outpatient use and improves compliance for chronic intestinal disease management.

Linaclotide Capsule's localized action and low systemic exposure enable its use in adults with mild hepatic or renal impairment (under guidance), broadening its clinical applicability.

Forecasting and Inventor

Accurate demand forecasting balances inventory and market needs by analyzing historical data, trends and external factors; predictive analytics tools boost accuracy with seasonality and supply disruptions factored in. Effective inventory management prevents stockouts and overstocking via regular turnover and forecast reviews to refine strategies.

Drivers of Demand and Future Trends

 

driving force:

• Disease Burden: The presence of Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation sustains a stable long-term demand for linaclotide.
• Expansion of Indications: FDA approval for new indications in 2023 has opened up new demand opportunities.
• Awareness: Improved global awareness of the diseases is driving growth in prescription volumes.

Future Trends:

• Expand clinical indications to underserved GI disorder subpopulations (e.g., refractory constipation, post-surgical bowel dysmotility).
• Innovate drug formulations (sustained-release, oral solutions, combinations) to boost adherence, efficacy and market differentiation.
• Penetrate Asia-Pacific, Latin America and Africa emerging markets via partnerships, local trials and tailored access programs for long-term growth.

Frequently Asked Questions

 

Hot Tags: linaclotide capsules 72 mcg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale